A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Clinical trial NCT05633355 · COMPLETED

Trial details

NCT number: NCT05633355
Sponsor: Amgen
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Atopic Dermatitis

Start date: 2023-01-30
Primary completion: 2025-07-31
Enrollment: 187

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.